Vivex Biomedical Inc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vivex Biomedical Inc
Regulating Cell Therapies: Conditional Approval Under Consideration In Congress; FDA Plans Public Hearing
Does FDA need a new pathway to consider advances in cellular therapy? Some in Congress think so. FDA is inviting stakeholders to weigh in this fall.
Start-ups raised $1.8 billion in Q1 2016. Biopharma companies penned 33 alliances; 14 acquisitions were signed (11 in the biopharma industry).
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced March-April 2016.
It’s the 10th anniversary of START-UP’s A-List, an analysis of the year’s Series A life science funding, and a highlight of the year’s most interesting new companies. Deal flow was up this year, as was the average disclosed amount of financing.
- Implantable Devices